Article

Vitamin E intake and risk of amyotrophic lateral sclerosis

Department of Nutrition, Harvard School of Public Health, 655 Huntington Avenue, Building 2, Boston, MA 02115, USA.
Annals of Neurology (Impact Factor: 11.91). 01/2005; 57(1):104-10. DOI: 10.1002/ana.20316
Source: PubMed

ABSTRACT Oxidative stress may contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS). We therefore examined prospectively whether individuals who regularly use supplements of the antioxidant vitamins E and C have a lower risk of ALS than nonusers. The study population comprised 957,740 individuals 30 years of age or older participating in the American Cancer Society's Cancer Prevention Study II. Information on vitamin use was collected at time of recruitment in 1982; participants then were followed up for ALS deaths from 1989 through 1998 via linkage with the National Death Index. During the follow-up, we documented 525 deaths from ALS. Regular use of vitamin E supplements was associated with a lower risk of dying of ALS. The age- and smoking-adjusted relative risk was 0.99 (95% confidence interval [CI], 0.69-1.41) among occasional users, 0.59 (95% CI, 0.36-0.96) in regular users for less than 10 years, and 0.38 (95% CI, 0.16-0.92) in regular users for 10 years or more as compared with nonusers of vitamin E (p for trend = 0.004). In contrast, no significant associations were found for use of vitamin C or multivitamins. These results suggest that vitamin E supplementation could have a role in ALS prevention.

0 Followers
 · 
73 Views
  • Source
    • "Numerous reports have suggested that all types of vitamin E scavenge reactive oxygen species and protect cells and organs against oxidative stress as their common potent characteristic [5] [6] [7]. Furthermore, recent epidemiological and clinical studies suggest that vitamin E is effective in oxidative stress-related neurodegenerative disorders such as Parkinson's disease (PD) [8] [9] [10], Alzheimer's disease [11], and amyotrophic lateral sclerosis [12]. However, other clinical studies have failed to confirm the efficacy of vitamin E members, especially αTOC, in the treatment of these diseases [13] [14] [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tocotrienols (T3s) are members of the vitamin E family, have antioxidant properties, and are promising candidates for neuroprotection in the pathogenesis of neurodegenerative disorders such as Parkinson’s disease (PD). However, whether their antioxidant capacities are required for their cytoprotective activity remains unclear. In this regard, the antioxidant-independent cytoprotective activity of T3s has received considerable attention. Here, we investigated the signaling pathways that are induced during T3-dependent cytoprotection of human neuroblastoma SH-SY5Y cells, as these cells are used to model certain elements of PD. T3s were cytoprotective against MPP+ and other PD-related toxicities. γT3 and δT3 treatment led to marked activation of the PI3K/Akt signaling pathway. Furthermore, we identified estrogen receptor (ER) β as an upstream mediator of PI3K/Akt signaling following γT3/δT3 stimulation. Highly purified γT3/δT3 bound to ERβ directly in vitro, and knockdown of ERβ in SH-SY5Y cells abrogated both γT3/δT3-dependent cytoprotection and Akt phosphorylation. Since membrane-bound ERβ was important for the signal-related cytoprotective effects of γT3/δT3, we investigated receptor-mediated caveola formation as a candidate for the early events of signal transduction. Knockdown of caveolin-1 and/or caveolin-2 prevented the cytoprotective effects of γT3/δT3, but did not affect Akt phosphorylation. This finding suggests that T3s and, in particular, γT3/δT3, exhibit not only antioxidant effects but also a receptor signal-mediated protective action following ERβ/PI3K/Akt signaling. Furthermore, receptor-mediated caveola formation is an important event during the early steps following T3 treatment.
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 01/2014; · 5.09 Impact Factor
  • Source
    • "Contents lists available at SciVerse ScienceDirect journal homepage: www.elsevier.com/locate/freeradbiomed development of ALS to 0.38 [12]. Also riluzole, the only approved neuroprotective treatment for ALS, is an antiglutamatergic agent which also has antioxidant properties [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Compelling evidence indicates that oxidative stress contributes to motor neuron injury in amyotrophic lateral sclerosis (ALS), but anti-oxidant therapies have not yet achieved therapeutic benefit in the clinic. The nuclear erythroid 2-related-factor 2 (Nrf2) transcription factor is a key regulator of an important neuroprotective response by driving the expression of multiple cytoprotective genes via its interaction with the anti-oxidant response element (ARE). Dysregulation of the Nrf2-ARE system has been identified in ALS models and the human disease. Taking the Nrf2-ARE pathway as an attractive therapeutic target for neuroprotection in ALS, we aimed to identify CNS penetrating, small molecule activators of Nrf2-mediated transcription in a library of 2000 drugs and natural products. Compounds were screened extensively for Nrf2 activation, anti-oxidant and neuroprotective properties in vitro. S[+]apomorphine, a receptor-inactive enantiomer of the clinically approved dopamine-receptor agonist (R[-]apomorphine), was identified as a non-toxic Nrf2 activating molecule. In vivo S[+]apomorphine demonstrated CNS penetrance, Nrf2 induction and significant attenuation of motor dysfunction in the SOD1(G93A) transgenic mouse model of ALS. S[+] apomorphine also reduced pathological oxidative stress and improved survival following an oxidative insult in fibroblasts from ALS patients. This molecule emerges as a promising candidate for evaluation as a potential neuroprotective agent in ALS patients in the clinic.
    Free Radical Biology and Medicine 04/2013; 61(100). DOI:10.1016/j.freeradbiomed.2013.04.018 · 5.71 Impact Factor
  • Source
    • "Similar results have been reported in human studies. Long-term use of vitamin E supplements in an ALS-free cohort was associated with a reduced risk of dying of ALS [208]. However, two clinical trials using oral administration of vitamin E at either 500 mg twice a day for 12 months [209] or 5000 mg/day for 18 months [210] showed no effect on survival in ALS patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by death of motor neurons leading to muscle wasting, paralysis, and death, usually within 2-3 years of symptom onset. The causes of ALS are not completely understood, and the neurodegenerative processes involved in disease progression are diverse and complex. There is substantial evidence implicating oxidative stress as a central mechanism by which motor neuron death occurs, including elevated markers of oxidative damage in ALS patient spinal cord and cerebrospinal fluid and mutations in the antioxidant enzyme superoxide dismutase 1 (SOD1) causing approximately 20% of familial ALS cases. However, the precise mechanism(s) by which mutant SOD1 leads to motor neuron degeneration has not been defined with certainty, and the ultimate trigger for increased oxidative stress in non-SOD1 cases remains unclear. Although some antioxidants have shown potential beneficial effects in animal models, human clinical trials of antioxidant therapies have so far been disappointing. Here, the evidence implicating oxidative stress in ALS pathogenesis is reviewed, along with how oxidative damage triggers or exacerbates other neurodegenerative processes, and we review the trials of a variety of antioxidants as potential therapies for ALS.
    Free Radical Biology and Medicine 12/2009; 48(5):629-41. DOI:10.1016/j.freeradbiomed.2009.11.018 · 5.71 Impact Factor
Show more

Preview

Download
2 Downloads